106 related articles for article (PubMed ID: 32011525)
21. Overall survival of patients with recurrent pancreatic cancer treated with systemic therapy: a retrospective study.
Gbolahan OB; Tong Y; Sehdev A; O'Neil B; Shahda S
BMC Cancer; 2019 May; 19(1):468. PubMed ID: 31101022
[TBL] [Abstract][Full Text] [Related]
22. The Role of 18F-FDG PET/CT and PET/MRI in Pancreatic Ductal Adenocarcinoma.
Yeh R; Dercle L; Garg I; Wang ZJ; Hough DM; Goenka AH
Abdom Radiol (NY); 2018 Feb; 43(2):415-434. PubMed ID: 29143875
[TBL] [Abstract][Full Text] [Related]
23. Preoperative Volume-Based PET Parameter, MTV2.5, as a Potential Surrogate Marker for Tumor Biology and Recurrence in Resected Pancreatic Cancer.
Kang CM; Lee SH; Hwang HK; Yun M; Lee WJ
Medicine (Baltimore); 2016 Mar; 95(9):e2595. PubMed ID: 26945350
[TBL] [Abstract][Full Text] [Related]
24. Perioperative EOX treatment in operable locally advanced gastroesophageal adenocarcinoma: Prediction of tumor response by FDG -PET and histopathology.
Vihervaara H; Ålgars A; Kemppainen J; Sundström J; Ristamäki R; Salminen P
Surg Oncol; 2019 Mar; 28():42-49. PubMed ID: 30851910
[TBL] [Abstract][Full Text] [Related]
25. Prediction of local tumor control and recurrence-free survival in patients with pancreatic cancer undergoing curative resection after neoadjuvant chemoradiotherapy.
Suto H; Okano K; Oshima M; Ando Y; Matsukawa H; Takahashi S; Shibata T; Kamada H; Masaki T; Suzuki Y
J Surg Oncol; 2022 Aug; 126(2):292-301. PubMed ID: 35289928
[TBL] [Abstract][Full Text] [Related]
26. The impact of neoadjuvant therapy on the histopathological features of pancreatic ductal adenocarcinoma - A systematic review and meta-analysis.
Schorn S; Demir IE; Reyes CM; Saricaoglu C; Samm N; Schirren R; Tieftrunk E; Hartmann D; Friess H; Ceyhan GO
Cancer Treat Rev; 2017 Apr; 55():96-106. PubMed ID: 28342938
[TBL] [Abstract][Full Text] [Related]
27. 18F-Fluorodeoxyglucose Positron Emission Tomography Predicts Treatment Efficacy and Clinical Outcome for Patients With Pancreatic Carcinoma: A Meta-analysis.
Wang L; Dong P; Shen G; Hou S; Zhang Y; Liu X; Tian B
Pancreas; 2019 Sep; 48(8):996-1002. PubMed ID: 31404025
[TBL] [Abstract][Full Text] [Related]
28. Neoadjuvant FOLFIRINOX for Patients with Borderline Resectable or Locally Advanced Pancreatic Cancer: Results of a Decision Analysis.
Choi JG; Nipp RD; Tramontano A; Ali A; Zhan T; Pandharipande P; Dowling EC; Ferrone CR; Hong TS; Schrag D; Fernandez-Del Castillo C; Ryan DP; Kong CY; Hur C
Oncologist; 2019 Jul; 24(7):945-954. PubMed ID: 30559125
[TBL] [Abstract][Full Text] [Related]
29. 18F-FDG PET/CT in pancreatic adenocarcinoma: A role at initial imaging staging?
Wartski M; Sauvanet A
Diagn Interv Imaging; 2019 Dec; 100(12):735-741. PubMed ID: 31402332
[TBL] [Abstract][Full Text] [Related]
30. [18F]-Fluorodeoxyglucose-positron emission tomography for the assessment of histopathologic response and prognosis after completion of neoadjuvant chemoradiation in esophageal cancer.
Vallböhmer D; Hölscher AH; Dietlein M; Bollschweiler E; Baldus SE; Mönig SP; Metzger R; Schicha H; Schmidt M
Ann Surg; 2009 Dec; 250(6):888-94. PubMed ID: 19953708
[TBL] [Abstract][Full Text] [Related]
31. Intraoperative Radiation Therapy (IORT) for Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (BR/LA PDAC) in the Era of Modern Neoadjuvant Treatment: Short-Term and Long-Term Outcomes.
Harrison JM; Wo JY; Ferrone CR; Horick NK; Keane FK; Qadan M; Lillemoe KD; Hong TS; Clark JW; Blaszkowsky LS; Allen JN; Castillo CF
Ann Surg Oncol; 2020 May; 27(5):1400-1406. PubMed ID: 31758284
[TBL] [Abstract][Full Text] [Related]
32. Preoperative High Maximum Standardized Uptake Value in Association with Glucose Transporter 1 Predicts Poor Prognosis in Pancreatic Cancer.
Chikamoto A; Inoue R; Komohara Y; Sakamaki K; Hashimoto D; Shiraishi S; Takamori H; Yamashita YI; Yoshida N; Yamanaka T; Yamashita Y; Baba H
Ann Surg Oncol; 2017 Jul; 24(7):2040-2046. PubMed ID: 28180987
[TBL] [Abstract][Full Text] [Related]
33. Clinical Usefulness of
Rinzivillo M; Partelli S; Prosperi D; Capurso G; Pizzichini P; Iannicelli E; Merola E; Muffatti F; Scopinaro F; Schillaci O; Salgarello M; Falconi M; Delle Fave G; Panzuto F
Oncologist; 2018 Feb; 23(2):186-192. PubMed ID: 29118267
[TBL] [Abstract][Full Text] [Related]
34. Borderline or locally advanced pancreatic adenocarcinoma: A single center experience on the FOLFIRINOX induction regimen.
Garnier J; Ewald J; Marchese U; Gilabert M; Moureau-Zabotto L; Giovannini M; Poizat F; Delpero JR; Turrini O
Eur J Surg Oncol; 2020 Aug; 46(8):1510-1515. PubMed ID: 32146053
[TBL] [Abstract][Full Text] [Related]
35. FOLFIRINOX-based neoadjuvant chemoradiotherapy for borderline and locally advanced pancreatic cancer: A pilot study from a tertiary centre.
Pouypoudat C; Buscail E; Cossin S; Cassinotto C; Terrebonne E; Blanc JF; Smith D; Marty M; Dupin C; Laurent C; Dabernat S; Chiche L; Vendrely V
Dig Liver Dis; 2019 Jul; 51(7):1043-1049. PubMed ID: 31000479
[TBL] [Abstract][Full Text] [Related]
36. Clinically determined type of 18F-fluoro-2-deoxyglucose uptake as an alternative prognostic marker in resectable pancreatic cancer.
Chong JU; Hwang HK; Lee JH; Yun M; Kang CM; Lee WJ
PLoS One; 2017; 12(2):e0172606. PubMed ID: 28235029
[TBL] [Abstract][Full Text] [Related]
37. Network meta-analysis comparing neoadjuvant chemoradiation, neoadjuvant chemotherapy and upfront surgery in patients with resectable, borderline resectable, and locally advanced pancreatic ductal adenocarcinoma.
Hu Q; Wang D; Chen Y; Li X; Cao P; Cao D
Radiat Oncol; 2019 Jul; 14(1):120. PubMed ID: 31291998
[TBL] [Abstract][Full Text] [Related]
38. Serum CA 19-9 response to neoadjuvant therapy is associated with outcome in pancreatic adenocarcinoma.
Boone BA; Steve J; Zenati MS; Hogg ME; Singhi AD; Bartlett DL; Zureikat AH; Bahary N; Zeh HJ
Ann Surg Oncol; 2014 Dec; 21(13):4351-8. PubMed ID: 25092157
[TBL] [Abstract][Full Text] [Related]
39. Prospective comparison of (4S)-4-(3-
Cheng MF; Huang YY; Ho BY; Kuo TC; Hsin LW; Shiue CY; Kuo HC; Jeng YM; Yen RF; Tien YW
Eur J Nucl Med Mol Imaging; 2019 Apr; 46(4):810-820. PubMed ID: 30635754
[TBL] [Abstract][Full Text] [Related]
40. Utility of contrast-enhanced FDG-PET/CT in the clinical management of pancreatic cancer: impact on diagnosis, staging, evaluation of treatment response, and detection of recurrence.
Asagi A; Ohta K; Nasu J; Tanada M; Nadano S; Nishimura R; Teramoto N; Yamamoto K; Inoue T; Iguchi H
Pancreas; 2013 Jan; 42(1):11-9. PubMed ID: 22699206
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]